Rollover Protocol for Prior SU011248 Protocols

Not Applicable

Completed

• Conditions: Solid Tumors
• Interventions: Drug: Sunitinib

• Registration Number: NCT00798889
• Lead Sponsor: Pfizer

Brief Summary

The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03
• Study First Submitted: 2008-11-25
• Study First Submitted QC: 2008-11-25
• Study First Posted: 2008-11-26
• Primary Completion: 2011-12
• Study Completion: 2011-12
• Status Verified: 2012-12
• Results First Submitted: 2012-12-13
• Results First Submitted QC: 2012-12-13
• Last Update Submitted: 2012-12-13
• Results First Posted: 2013-01-21
• Last Update Posted: 2013-01-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 314

Inclusion Criteria

• Prior SU011248 Protocol.
• Eligible to continue SU011248 treatment.

Exclusion Criteria

• Uncontrolled CNS metastasis.
• Unfit to receive SU011248.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Sunitinib	Sunitinib	-

Primary Outcome Measures

Name	Time	Method
Duration of Treatment	Baseline up to Day 28 after last dose of study treatment

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇬🇧 Newcastle-Upon-Tyne, United Kingdom